Verve Stock Analysis

VERV
 Stock
  

USD 21.42  2.58  10.75%   

The latest fall in stock price may raise some interest from sophisticated investors as it is trading at a share price of 21.42 on 2,426,409 in trading volume. The company executives have failed to build on market volatilities in November. However, diversifying your overall positions with Verve Therapeutics may protect your principal portfolio during upcoming market swings. The stock standard deviation of daily returns for 90 days investing horizon is currently 6.98. The very high volatility is mostly attributed to the latest market swings and not very good earnings reports from some of the Verve Therapeutics partners.
Also, please take a look at World Market Map.
  
The Verve Therapeutics stock analysis report makes it easy to digest most publicly released information about Verve Therapeutics and get updates on important government artifacts, including earning estimates, SEC corporate filings, and announcements. Verve Stock analysis module also helps to analyze the Verve Therapeutics price relationship with some important fundamental indicators such as market cap and management efficiency.

Verve Stock Analysis Notes

About 90.0% of the company outstanding shares are owned by institutional investors. The book value of Verve Therapeutics was at this time reported as 9.07. The company recorded earning per share (EPS) of 8.55. Verve Therapeutics had not issued any dividends in recent years. Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Verve Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts. Verve Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 113 people. For more information please call Sekar MD at 617 603 0070 or visit https://www.vervetx.com.

Verve Therapeutics Investment Alerts

Many investors view ongoing market volatility as an opportunity to purchase more stocks at a favorable price or short it to generate a bearish trend profit opportunity. If you are one of those investors, make sure you clearly understand the position you are entering. Verve Therapeutics' investment alerts are automatically generated signals that are significant enough to either complement your investing judgment regarding Verve Therapeutics or challenge it. These alerts can help you understand what you are buying and avoid costly mistakes.
Verve Therapeutics generated a negative expected return over the last 90 days
Verve Therapeutics has high historical volatility and very poor performance
Net Loss for the year was (120.31 M) with profit before overhead, payroll, taxes, and interest of 0.
Verve Therapeutics currently holds about 293.56 M in cash with (77.88 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.9.
Over 90.0% of the company outstanding shares are owned by institutional investors

Verve Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Verve Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Verve Therapeutics backward and forwards among themselves. Verve Therapeutics' institutional investor refers to the entity that pools money to purchase Verve Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Security TypeSharesValue
Zurcher Kantonalbank Zurich CantonalbankCommon Shares4.6 K158 K
Zurcher Kantonalbank Zurich CantonalbankCommon Shares2.9 K45 K
Zurcher Kantonalbank Zurich CantonalbankCommon Shares2.9 K67 K
Woodline Partners LpCommon Shares375 K12.9 M
Woodline Partners LpCommon Shares150 K2.3 M
Woodline Partners LpCommon Shares150 K3.4 M
Woodline Partners LpCommon Shares176 K6.5 M
Note, although Verve Therapeutics' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Verve Market Capitalization

The company currently falls under 'Mid-Cap' category with current market capitalization of 1.48 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Verve Therapeutics's market, we take the total number of its shares issued and multiply it by Verve Therapeutics's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities.

Management Efficiency

The entity has return on total asset (ROA) of (0.1735) % which means that it has lost $0.1735 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (0.3165) %, meaning that it created substantial loss on money invested by shareholders. Verve Therapeutics management efficiency ratios could be used to measure how well verve therapeutics manages its routine affairs as well as how well it operates its assets and liabilities.

Technical Drivers

As of the 5th of December, Verve Therapeutics has the risk adjusted performance of (0.1), and Coefficient Of Variation of (1,430). In relation to fundamental indicators, the technical analysis model makes it possible for you to check existing technical drivers of Verve Therapeutics, as well as the relationship between them. In other words, you can use this information to find out if the company will indeed mirror its model of past prices and volume data, or the prices will eventually revert. We were able to interpolate data for nineteen technical drivers for Verve Therapeutics, which can be compared to its competition. Please validate Verve Therapeutics jensen alpha and semi variance to decide if Verve Therapeutics is priced more or less accurately, providing market reflects its prevalent price of 21.42 per share. Given that Verve Therapeutics has jensen alpha of (0.66), we advise you to double-check Verve Therapeutics's current market performance to make sure the company can sustain itself at a future point.

Verve Therapeutics Price Movement Analysis

Execute Study
Incorrect Input. Please change your parameters or increase the time horizon required for running this function. The output start index for this execution was zero with a total number of output elements of zero. The Bollinger Bands is very popular indicator that was developed by John Bollinger. It consist of three lines. Verve Therapeutics middle band is a simple moving average of its typical price. The upper and lower bands are (N) standard deviations above and below the middle band. The bands widen and narrow when the volatility of the price is higher or lower, respectively. The upper and lower bands can also be interpreted as price targets for Verve Therapeutics. When the price bounces off of the lower band and crosses the middle band, then the upper band becomes the price target.
.

Verve Therapeutics Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Verve Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Verve Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Verve Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Yeshwant Krishna over three weeks ago via Macroaxis 
Acquisition or disposition of Verve Therapeutics securities by Yeshwant Krishna
Yeshwant Krishna over a month ago via Macroaxis 
Acquisition or disposition of Verve Therapeutics securities by Yeshwant Krishna
Yeshwant Krishna over a month ago via Macroaxis 
Acquisition or disposition of Verve Therapeutics securities by Yeshwant Krishna
Kathiresan Sekar over a month ago via Macroaxis 
Verve Therapeutics exotic insider transaction detected
Kathiresan Sekar over two months ago via Macroaxis 
Exercise or conversion by Kathiresan Sekar of 50000 shares of Verve Therapeutics subject to Rule 16b-3
Kathiresan Sekar over two months ago via Macroaxis 
Sale by Kathiresan Sekar of 11185 shares of Verve Therapeutics
Bellinger Andrew over two months ago via Macroaxis 
Exercise or conversion by Bellinger Andrew of 20000 shares of Verve Therapeutics subject to Rule 16b-3
Ashe Andrew D over three months ago via Macroaxis 
Exercise or conversion by Ashe Andrew D of 10835 shares of Verve Therapeutics subject to Rule 16b-3
Kathiresan Sekar over three months ago via Macroaxis 
Exercise or conversion by Kathiresan Sekar of 50000 shares of Verve Therapeutics subject to Rule 16b-3
Coats Lonnel over three months ago via Macroaxis 
Acquisition by Coats Lonnel of 31000 shares of Verve Therapeutics subject to Rule 16b-3
Fmr Llc over three months ago via Macroaxis 
Verve Therapeutics exotic insider transaction detected
Kathiresan Sekar over three months ago via Macroaxis 
Exercise or conversion by Kathiresan Sekar of 50000 shares of Verve Therapeutics subject to Rule 16b-3

Verve Therapeutics Predictive Daily Indicators

Verve Therapeutics intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Verve Therapeutics stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.

Verve Therapeutics Forecast Models

Verve Therapeutics time-series forecasting models is one of many Verve Therapeutics' stock analysis techniquest aimed to predict future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Verve Therapeutics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

About Verve Stock Analysis

Stock analysis is the technique used by a trader or investor to examine and evaluate how Verve Therapeutics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Verve shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas, a specific sector, or an individual Stock such as Verve Therapeutics. By using and applying Verve Stock analysis, traders can create a robust methodology for identifying Verve entry and exit points for their positions.
Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Verve Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts. Verve Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 113 people.

Be your own money manager

As an investor, your ultimate goal is to build wealth. Optimizing your investment portfolio is an essential element in this goal. Using our stock analysis tools, you can find out how much better you can do when adding Verve Therapeutics to your portfolios without increasing risk or reducing expected return.

Did you try this?

Run Portfolio Comparator Now

   

Portfolio Comparator

Compare the composition, asset allocations and performance of any two portfolios in your account
All  Next Launch Module
Also, please take a look at World Market Map. You can also try Companies Directory module to evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals.

Complementary Tools for analysis

When running Verve Therapeutics price analysis, check to measure Verve Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Verve Therapeutics is operating at the current time. Most of Verve Therapeutics' value examination focuses on studying past and present price action to predict the probability of Verve Therapeutics' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Verve Therapeutics' price. Additionally, you may evaluate how the addition of Verve Therapeutics to your portfolios can decrease your overall portfolio volatility.
Transaction History
View history of all your transactions and understand their impact on performance
Go
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Go
Companies Directory
Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals
Go
Analyst Recommendations
Analyst recommendations and target price estimates broken down by several categories
Go
Pattern Recognition
Use different Pattern Recognition models to time the market across multiple global exchanges
Go
CEO Directory
Screen CEOs from public companies around the world
Go
Price Transformation
Use Price Transformation models to analyze depth of different equity instruments across global markets
Go
Is Verve Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Verve Therapeutics. If investors know Verve will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Verve Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Market Capitalization
1.5 B
Return On Assets
(0.17) 
Return On Equity
(0.32) 
The market value of Verve Therapeutics is measured differently than its book value, which is the value of Verve that is recorded on the company's balance sheet. Investors also form their own opinion of Verve Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Verve Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Verve Therapeutics' market value can be influenced by many factors that don't directly affect Verve Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Verve Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine Verve Therapeutics value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Verve Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.